This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004; 22: 1583-8. 10.1200/JCO.2004.06.082RoaWBrasherPMBaumanGAnthesMBrueraEChanAAbbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trialJ Clin Oncol2004221583810.1200/JCO.2004.06.082Open DOISearch in Google Scholar
Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012; 13: 916-26. 10.1016/S1470-2045(12)70265-6MalmströmAGrønbergBHMarosiCStuppRFrappazDSchultzHTemozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trialLancet Oncol2012139162610.1016/S1470-2045(12)70265-6Open DOISearch in Google Scholar
Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial. Lancet Oncol 2012; 13: 707-15. 10.1016/S1470-2045(12)70164-XWickWPlattenMMeisnerCFelsbergJTabatabaiGSimonMTemozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trialLancet Oncol2012137071510.1016/S1470-2045(12)70164-XOpen DOISearch in Google Scholar
Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 2017; 376: 1027-37. 10.1056/NEJMoa1611977PerryJRLaperriereNO’CallaghanCJBrandesAAMentenJPhillipsCShort-course radiation plus temozolomide in elderly patients with glioblastomaN Engl J Med201737610273710.1056/NEJMoa1611977Open DOISearch in Google Scholar
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.HegiMEDiserensACGorliaTHamouMFde TriboletNWellerMMGMT gene silencing and benefit from temozolomide in glioblastomaN Engl J Med2005352997100310.1056/NEJMoa043331Search in Google Scholar
Wick W, Platten M, Wick A, Hertenstein A, Radbruch A, Bendszus M, et al. Current status and future directions of anti-angiogenic therapy for gliomas. Neuro Oncol 2016; 18: 315-28. 10.1093/neuonc/nov180WickWPlattenMWickAHertensteinARadbruchABendszusMCurrent status and future directions of anti-angiogenic therapy for gliomasNeuro Oncol2016183152810.1093/neuonc/nov180Open DOISearch in Google Scholar
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370: 709-22. 10.1056/NEJMoa1308345ChinotOLWickWMasonWHenrikssonRSaranFNishikawaRBevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastomaN Engl J Med20143707092210.1056/NEJMoa1308345Open DOISearch in Google Scholar
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A Randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370: 699-708. 10.1056/NEJMoa1308573GilbertMRDignamJJArmstrongTSWefelJSBlumenthalDTVogelbaumMAA Randomized trial of bevacizumab for newly diagnosed glioblastomaN Engl J Med201437069970810.1056/NEJMoa1308573Open DOISearch in Google Scholar
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-66. 10.1016/S1470-2045(09)70025-7StuppRHegiMEMasonWPvan den BentMJTaphoornMJBJanzerRCEffects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialLancet Oncol2009104596610.1016/S1470-2045(09)70025-7Open DOISearch in Google Scholar
Uhm JH, Porter AB. Treatment of Glioma in the 21st Century: An exciting decade of postsurgical treatment advances in the molecular era. Mayo Clin Proc 2017; 92: 995-1004. 10.1016/j.mayocp.2017.01.010UhmJHPorterAB.Treatment of Glioma in the 21st Century: An exciting decade of postsurgical treatment advances in the molecular eraMayo Clin Proc201792995100410.1016/j.mayocp.2017.01.010Open DOISearch in Google Scholar
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96. 10.1056/NEJMoa043330StuppRMasonWPvan den BentMJWellerMFisherBTaphoornMJBRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med20053529879610.1056/NEJMoa043330Open DOISearch in Google Scholar
Alexander BM, Cloughesy TF. Adult glioblastoma. J Clin Oncol 2017; 35: 2402-09. 10.1200/JCO.2017.73.0119AlexanderBMCloughesyTF.Adult glioblastomaJ Clin Oncol20173524020910.1200/JCO.2017.73.0119Open DOISearch in Google Scholar
Halasz BLM, Soltys SG, Breneman JC, Chan MD, Laack NN, Minniti G, et al. Treatment of gliomas: a changing landscape. Int J Radiat Oncol Biol Phys 2017; 98: 255-8. 10.1016/j.ijrobp.2017.02.223HalaszBLMSoltysSGBrenemanJCChanMDLaackNNMinnitiGTreatment of gliomas: a changing landscapeInt J Radiat Oncol Biol Phys201798255810.1016/j.ijrobp.2017.02.223Open DOISearch in Google Scholar
Hottinger AF, Pacheco P, Stupp R. Tumor treating fields: a novel treatment modality and its use in brain tumors. Neuro Oncol 2016; 18: 1338-49. 10.1093/neuonc/now182HottingerAFPachecoPStuppR.Tumor treating fields: a novel treatment modality and its use in brain tumorsNeuro Oncol20161813384910.1093/neuonc/now182Open DOISearch in Google Scholar
Mehta M, Wen P, Nishikawa R, Reardon D, Peters K. Critical Reviews in Oncology / Hematology Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Crit Rev Oncol Hematol 2017; 111: 60-5. 10.1016/j.critrevonc.2017.01.005MehtaMWenPNishikawaRReardonDPetersK.Critical Reviews in Oncology / Hematology Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patientsCrit Rev Oncol Hematol201711160510.1016/j.critrevonc.2017.01.005Open DOISearch in Google Scholar
Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma. JAMA 2015; 314: 2535-43. 10.1001/jama.2015.16669StuppRTaillibertSKannerAAKesariSSteinbergDMTomsSAMaintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastomaJAMA201531425354310.1001/jama.2015.16669Open DOISearch in Google Scholar
Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, et al. Effect of Tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA 2017; 318: 2306-16. 10.1001/jama.2017.18718StuppRTaillibertSKannerAReadWSteinbergDMLhermitteBEffect of Tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trialJAMA201731823061610.1001/jama.2017.18718Open DOISearch in Google Scholar
Wick W. TTFields: Where does all the skepticism come from? Neuro Oncol 2016; 18: 303-5. 10.1093/neuonc/now012WickW.TTFields: Where does all the skepticism come from?Neuro Oncol201618303510.1093/neuonc/now012Open DOISearch in Google Scholar
Zhu JJ, Demireva P, Kanner AA, Pannullo S, Mehdorn M, Avgeropoulos N, et al. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. J Neurooncol 2017 Aug 28. 10.1007/s11060-017-2601-y. [Epub ahead of print]ZhuJJDemirevaPKannerAAPannulloSMehdornMAvgeropoulosNHealth-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastomaJ Neurooncol2017Aug 2810.1007/s11060-017-2601-y[Epub ahead of print]Open DOISearch in Google Scholar
Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 2017; 18: 1373-85. 10.1016/S1470-2045(17)30517-XWellerMButowskiNTranDDRechtLDLimMHirteHRindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialLancet Oncol20171813738510.1016/S1470-2045(17)30517-XOpen DOISearch in Google Scholar
Corso CD, Bindra RS, Mehta MP. The role of radiation in treating glioblastoma: here to stay. J Neurooncol 2017 Mar 7. 10.1007/s11060-016-2348-x. [Epub ahead of print]CorsoCDBindraRSMehtaMP.The role of radiation in treating glioblastoma: here to stayJ Neurooncol2017Mar 710.1007/s11060-016-2348-x[Epub ahead of print]Open DOISearch in Google Scholar
Roth P, Gramatzki D, Weller M. Management of elderly patients with glioblastoma. Curr Neurol Neurosci Rep 2017; 17: 35. 10.1007/s11910-017-0740-3RothPGramatzkiDWellerM.Management of elderly patients with glioblastomaCurr Neurol Neurosci Rep2017173510.1007/s11910-017-0740-3Open DOISearch in Google Scholar
Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979; 5: 1725-31. 10.1016/0360-3016(79)90553-4WalkerMDStrikeTAShelineGE.An analysis of dose-effect relationship in the radiotherapy of malignant gliomasInt J Radiat Oncol Biol Phys1979517253110.1016/0360-3016(79)90553-4Open DOISearch in Google Scholar
Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983; 52:997-1007.ChangCHHortonJSchoenfeldDSalazerOPerez-TamayoRKramerSComparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group studyCancer198352997100710.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2Search in Google Scholar
Chan JL, Lee SW, Fraass BA, Normolle DP, Greenberg HS, Junck LR, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002; 20: 1635-42.ChanJLLeeSWFraassBANormolleDPGreenbergHSJunckLRSurvival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapyJ Clin Oncol20022016354210.1200/JCO.2002.20.6.1635Search in Google Scholar
Selker RG, Shapiro WR, Burger P, Blackwood MS, Arena VC, Gilder JC, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 2002; 51: 343-57.SelkerRGShapiroWRBurgerPBlackwoodMSArenaVCGilderJCThe Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustineNeurosurgery2002513435710.1097/00006123-200208000-00009Search in Google Scholar
Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004; 60: 853-60. 10.1016/j.ijrobp.2004.04.011SouhamiLSeiferheldWBrachmanDPodgorsakEBWerner-WasikMLustigRRandomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocolInt J Radiat Oncol Biol Phys2004608536010.1016/j.ijrobp.2004.04.011Open DOISearch in Google Scholar
Werner-Wasik M, Scott CB, Nelson DF, Gaspar LE, Murray KJ, Fischbach JA, et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02. Cancer 1996; 77: 1535-43.Werner-WasikMScottCBNelsonDFGasparLEMurrayKJFischbachJAFinal report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02Cancer19967715354310.1002/(SICI)1097-0142(19960415)77:8<1535::AID-CNCR17>3.0.CO;2-0Search in Google Scholar
Badiyan SN, Markovina S, Simpson JR, Robinson CG, DeWees T, Tran DD, et al. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide. Int J Radiat Oncol Biol Phys 2014; 90: 877-85. 10.1016/j.ijrobp.2014.07.014BadiyanSNMarkovinaSSimpsonJRRobinsonCGDeWeesTTranDDRadiation therapy dose escalation for glioblastoma multiforme in the era of temozolomideInt J Radiat Oncol Biol Phys2014908778510.1016/j.ijrobp.2014.07.014Open DOISearch in Google Scholar
Kelly PJ, Daumas-Duport C, Scheithauer BW, Kall BA KD. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987; 62: 450-9.KellyPJDaumas-DuportCScheithauerBWKallBA KD.Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasmsMayo Clin Proc198762450910.1016/S0025-6196(12)65470-6Search in Google Scholar
Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro Oncol 2016; 18: 426-34. 10.1093/neuonc/nov148DunetVPomoniAHottingerANicod-LalondeMPriorJO.Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysisNeuro Oncol2016184263410.1093/neuonc/nov148Open DOISearch in Google Scholar
Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 2016; 18: 1199-208. 10.1093/neuonc/now058AlbertNLWellerMSuchorskaBGalldiksNSoffiettiRKimMMResponse assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomasNeuro Oncol201618119920810.1093/neuonc/now058Open DOISearch in Google Scholar
Whitfield GA, Kennedy SR, Djoukhadar IK, Jackson A. Imaging and target volume delineation in glioma. Clin Oncol (R Coll Radiol) 2014; 26: 364-76. 10.1016/j.clon.2014.04.026WhitfieldGAKennedySRDjoukhadarIKJacksonA.Imaging and target volume delineation in gliomaClin Oncol (R Coll Radiol)2014263647610.1016/j.clon.2014.04.026Open DOISearch in Google Scholar
Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, et al. Biopsy validation of 18 F-DOPA PET and planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol 2013; 15: 1058-67. 10.1093/neuonc/not002PafundiDHLaackNNYoulandRSParneyIFLoweVJGianniniCBiopsy validation of 18 F-DOPA PET and planning and radiotherapy target delineation: results of a prospective pilot studyNeuro Oncol20131510586710.1093/neuonc/not002Open DOISearch in Google Scholar
Mills SJ, Du Plessis D, Pal P, Thompson G, Buonacorrsi G, Soh C, et al. Mitotic activity in glioblastoma correlates with estimated extravascular extracellular space derived from dynamic contrast-enhanced MR imaging. Am J Neuroradiol 2016; 37: 811-7. 10.3174/ajnr.A4623MillsSJDu PlessisDPalPThompsonGBuonacorrsiGSohCMitotic activity in glioblastoma correlates with estimated extravascular extracellular space derived from dynamic contrast-enhanced MR imagingAm J Neuroradiol201637811710.3174/ajnr.A4623Open DOISearch in Google Scholar
Brindle KM, Izquierdo-García JL, Lewis DY, Mair RJ, Wright AJ. Brain tumor imaging. J Clin Oncol 2017; 35: 2432-8. 10.1200/JCO.2017.72.7636BrindleKMIzquierdo-GarcíaJLLewisDYMairRJWrightAJ.Brain tumor imagingJ Clin Oncol2017352432810.1200/JCO.2017.72.7636Open DOISearch in Google Scholar
Niyazi M, Geisler J, Siefert A, Schwarz SB, Ganswindt U, Garny S, et al. FET-PET for malignant glioma treatment planning. Radiother Oncol 2011; 99: 44-8. 10.1016/j.radonc.2011.03.001NiyaziMGeislerJSiefertASchwarzSBGanswindtUGarnySFET-PET for malignant glioma treatment planningRadiother Oncol20119944810.1016/j.radonc.2011.03.001Open DOISearch in Google Scholar
Sulman EP, Ismaila N, Armstrong TS, Tsien C, Batchelor TT, Cloughesy T, et al. Radiation therapy for glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. J Clin Oncol 2017; 35: 361-9. 10.1200/JCO.2016.70.7562SulmanEPIsmailaNArmstrongTSTsienCBatchelorTTCloughesyTRadiation therapy for glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology GuidelineJ Clin Oncol201735361910.1200/JCO.2016.70.7562Open DOISearch in Google Scholar
Niyazi M, Brada M, Chalmers AJ, Combs SE, Erridge SC, Fiorentino A, et al. ESTRO-ACROP guideline “target delineation of glioblastomas.” Radiother Oncol 2016; 118: 35-42. 10.1016/j.radonc.2015.12.003NiyaziMBradaMChalmersAJCombsSEErridgeSCFiorentinoAESTRO-ACROP guideline “target delineation of glioblastomas.”Radiother Oncol2016118354210.1016/j.radonc.2015.12.003Open DOISearch in Google Scholar
Minniti G, Amelio D, Amichetti M, Salvati M, Muni R, Bozzao A, et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 2010; 97: 377-81. 10.1016/j.radonc.2010.08.020MinnitiGAmelioDAmichettiMSalvatiMMuniRBozzaoAPatterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomideRadiother Oncol2010973778110.1016/j.radonc.2010.08.020Open DOISearch in Google Scholar
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella D, Webster B, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016; 131:803-20. 10.1007/s00401-016-1545-1LouisDNPerryAReifenbergerGvon DeimlingAFigarellaDWebsterBThe 2016 World Health Organization classification of tumors of the central nervous system: a summaryActa Neuropathol20161318032010.1007/s00401-016-1545-1Open DOISearch in Google Scholar
Chan MF, Schupak K, Burman C, Chui C-S, Ling CC. Comparison of intensity-modulated radiotherapy with three-dimensional conformal radiation therapy planning for glioblastoma multiforme. Med Dosim 2003; 28:261-5. 10.1016/j.meddos.2003.08.004ChanMFSchupakKBurmanCChuiC-SLingCC.Comparison of intensity-modulated radiotherapy with three-dimensional conformal radiation therapy planning for glioblastoma multiformeMed Dosim200328261510.1016/j.meddos.2003.08.004Open DOISearch in Google Scholar
Panet-Raymond V, Souhami L, Roberge D, Kavan P, Shakibnia L, Muanza T, et al. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. Int J Radiat Oncol Biol Phys 2009; 73: 473-8. 10.1016/j.ijrobp.2008.04.030Panet-RaymondVSouhamiLRobergeDKavanPShakibniaLMuanzaTAccelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysisInt J Radiat Oncol Biol Phys200973473810.1016/j.ijrobp.2008.04.030Open DOISearch in Google Scholar
Shenouda G, Souhami L, Petrecca K, Owen S, Panet-Raymond V, Guiot M-C, et al. A phase 2 trial of neoadjuvant temozolomide followed by hypofractionated accelerated radiation therapy with concurrent and adjuvant temozolomide for patients with glioblastoma. Int J Radiat Oncol Biol Phys 2017; 97: 487-94. 10.1016/j.ijrobp.2016.11.006ShenoudaGSouhamiLPetreccaKOwenSPanet-RaymondVGuiotM-CA phase 2 trial of neoadjuvant temozolomide followed by hypofractionated accelerated radiation therapy with concurrent and adjuvant temozolomide for patients with glioblastomaInt J Radiat Oncol Biol Phys2017974879410.1016/j.ijrobp.2016.11.006Open DOISearch in Google Scholar
Ataman F, Poortmans P, Stupp R, Fisher B, Mirimanoff RO. Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review. Eur J Cancer 2004; 40: 1724-30. 10.1016/j.ejca.2004.03.026AtamanFPoortmansPStuppRFisherBMirimanoffRO.Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case reviewEur J Cancer20044017243010.1016/j.ejca.2004.03.026Open DOISearch in Google Scholar
Kazda T, Jancalek R, Pospisil P, Sevela O, Prochazka T, Vrzal M, et al. Why and how to spare the hippocampus during brain radiotherapy: the developing role of hippocampal avoidance in cranial radiotherapy. Radiat Oncol 2014; 9: 139. 10.1186/1748-717X-9-139KazdaTJancalekRPospisilPSevelaOProchazkaTVrzalMWhy and how to spare the hippocampus during brain radiotherapy: the developing role of hippocampal avoidance in cranial radiotherapyRadiat Oncol2014913910.1186/1748-717X-9-139Open DOISearch in Google Scholar
Gondi V, Hermann BP, Mehta MP, Tomé WA. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys 2013; 85: 348-54. 10.1016/j.ijrobp.2012.11.031GondiVHermannBPMehtaMPToméWA.Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumorsInt J Radiat Oncol Biol Phys2013853485410.1016/j.ijrobp.2012.11.031Open DOISearch in Google Scholar
Gzell C, Back M, Wheeler H, Bailey D, Foote M. Radiotherapy in glioblastoma: the past, the present and the future. Clin Oncol (R Coll Radiol) 2017; 29: 15-25. 10.1016/j.clon.2016.09.015GzellCBackMWheelerHBaileyDFooteM.Radiotherapy in glioblastoma: the past, the present and the futureClin Oncol (R Coll Radiol)201729152510.1016/j.clon.2016.09.015Open DOISearch in Google Scholar
Smith AW, Mehta MP, Wernicke AG. Neural stem cells, the subventricular zone and radiotherapy: implications for treating glioblastoma. J Neurooncol 2016; 128: 1-10. 10.1007/s11060-016-2123-zSmithAWMehtaMPWernickeAG.Neural stem cells, the subventricular zone and radiotherapy: implications for treating glioblastomaJ Neurooncol201612811010.1007/s11060-016-2123-zOpen DOISearch in Google Scholar
Chen L, Chaichana KL, Kleinberg L, Ye X, Quinones-Hinojosa A, Redmond K. Glioblastoma recurrence patterns near neural stem cell regions. Radiother Oncol 2015; 116: 294-300. 10.1016/j.radonc.2015.07.032ChenLChaichanaKLKleinbergLYeXQuinones-HinojosaARedmondK.Glioblastoma recurrence patterns near neural stem cell regionsRadiother Oncol201511629430010.1016/j.radonc.2015.07.032Open DOISearch in Google Scholar
Khalifa J, Tensaouti F, Lusque A, Plas B, Lotterie J-A, Benouaich-Amiel A, et al. Subventricular zones: new key targets for glioblastoma treatment. Radiat Oncol 2017; 12: 67. 10.1186/s13014-017-0791-2KhalifaJTensaoutiFLusqueAPlasBLotterieJ-ABenouaich-AmielASubventricular zones: new key targets for glioblastoma treatmentRadiat Oncol2017126710.1186/s13014-017-0791-2Open DOISearch in Google Scholar
Nourallah B, Digpal R, Jena R, Watts C. Irradiating the subventricular zone in glioblastoma patients: is there a case for a clinical trial? Clin Oncol (R Coll Radiol) 2017; 29: 26-33. 10.1016/j.clon.2016.09.005NourallahBDigpalRJenaRWattsC.Irradiating the subventricular zone in glioblastoma patients: is there a case for a clinical trial?Clin Oncol (R Coll Radiol)201729263310.1016/j.clon.2016.09.005Open DOISearch in Google Scholar
Pospisil P, Kazda T, Hynkova L, Bulik M, Dobiaskova M, Burkon P, et al. Post-WBRT cognitive impairment and hippocampal neuronal depletion measured by in vivo metabolic MR spectroscopy: results of prospective investigational study. Radiother Oncol 2017; 122: 373-9. 10.1016/j.radonc.2016.12.013PospisilPKazdaTHynkovaLBulikMDobiaskovaMBurkonPPost-WBRT cognitive impairment and hippocampal neuronal depletion measured by in vivo metabolic MR spectroscopy: results of prospective investigational studyRadiother Oncol2017122373910.1016/j.radonc.2016.12.013Open DOISearch in Google Scholar
Flechl B, Sax C, Ackerl M, Crevenna R, Woehrer A, Hainfellner J, et al. The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma. Radiother Oncol 2017; 125: 228-33. 10.1016/j.radonc.2017.07.027FlechlBSaxCAckerlMCrevennaRWoehrerAHainfellnerJThe course of quality of life and neurocognition in newly diagnosed patients with glioblastomaRadiother Oncol20171252283310.1016/j.radonc.2017.07.027Open DOISearch in Google Scholar
Weller M, Roth P, Preusser M, Wick W, Reardon DA, Platten M, et al. Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol 2017; 13: 363-74. 10.1038/nrneurol.2017.64WellerMRothPPreusserMWickWReardonDAPlattenMVaccine-based immunotherapeutic approaches to gliomas and beyondNat Rev Neurol2017133637410.1038/nrneurol.2017.64Open DOISearch in Google Scholar
Sampson JH, Maus MV, June CH. Immunotherapy for brain tumors. J Clin Oncol 2017; 35: 2450-6. 10.1200/JCO.2017.72.8089SampsonJHMausMVJuneCH.Immunotherapy for brain tumorsJ Clin Oncol2017352450610.1200/JCO.2017.72.8089Open DOISearch in Google Scholar
Reznik E, Smith AW, Taube S, Mann J, Yondorf MZ, Parashar B, et al. Radiation and immunotherapy in high-grade gliomas. Am J Clin Oncol 2017 Sep 12. 10.1097/COC.0000000000000406. [Epub ahead of print]ReznikESmithAWTaubeSMannJYondorfMZParasharBRadiation and immunotherapy in high-grade gliomasAm J Clin Oncol2017Sep 1210.1097/COC.0000000000000406[Epub ahead of print]Open DOISearch in Google Scholar
